Disease · MONDO_0003472

lice infestation

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lice infestation. Diseases, record MONDO_0003472. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003472

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lice infestation; Open Targets
Open Targets ID: MONDO_0003472; Open Targets
Other names: Pediculus humanus infection, louse infestation (& [pediculosis and Phthirus] or [lice]), mixed pediculosis infestation, pediculosis, pediculosis and Phthirus infestation, pediculosis, unspecified; Open Targets
Disease Ontology: DOID:5502; Disease Ontology
MeSH: D010373; MeSH
NCI Thesaurus: C128401; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 7 drugs, from DailyMed and FDA; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ABAMETAPIR	CHEMBL2205807	Small molecule	Approval	FDA	6	5	5	Drugs and targets
SPINOSAD	CHEMBL4297065	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets
BENZYL ALCOHOL	CHEMBL720	Small molecule	Approval	DailyMed	4	1	1	Drugs and targets
IVERMECTIN	CHEMBL6067487		Approval	DailyMed	2	1	1	Drugs and targets
COCO DIETHANOLAMIDE	CHEMBL4297547		Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DIMETHICONE	CHEMBL2108200		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PERMETHRIN	CHEMBL1525	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02060903	A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation	Phase 3	379	2020-09-23	Head Lice Infestation	ABAMETAPIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT03337490	A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice	Phase 3	296	2020-09-17	Head Lice	IVERMECTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02624843	Bioequivalence Study for Benzyl Alcohol Lotion 5%.	Phase 3	239	2020-09-03	Head Lice	BENZYL ALCOHOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02213055	Pediatric Head Lice Study Product Comparison	Phase 2	97	2016-07-29	Head Lice	DIMETHICONE	Its record names the disease	ClinicalTrials.gov
NCT02097485	Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation	Phase 2	50	2021-05-11	Head Lice Infestation	ABAMETAPIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT01907490	Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation	Phase 2	38	2015-02-09	Head Lice Infestation	ABAMETAPIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT02062060	Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation	Phase 3	325		Head Lice Infestation	ABAMETAPIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT02499549	Two Treatment Regimens of Cocamide DEA Lotion for Head Lice	Phase 2/3	112		Pediculosis, Head Louse Infestation	COCO DIETHANOLAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00858481	A Pilot Dose Ranging Study of Spinosad Creme Rinse	Phase 2	36		Pediculosis Capitis, Head Lice	SPINOSAD	Open Targets' reading of its record	ClinicalTrials.gov
NCT00857935	A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse	Phase 2	24		Pediculosis Capitis, Head Lice	PERMETHRIN, SPINOSAD	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Abametapir Lotion 0.74% w/w vs Vehicle Lotion: deaths from any cause	0 of 186	0 of 188	374	NCT02060903	Trial comparisons
Abametapir Lotion 0.74% w/w vs Vehicle Lotion: serious adverse events	0 of 186	1 of 188	374	NCT02060903	Trial comparisons
Abametapir Lotion 0.74% w/w vs Vehicle Lotion: Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.	43 of 53	28 of 55	108	NCT02060903	Trial comparisons
Abametapir Lotion 0.74% w/w vs Vehicle Lotion: deaths from any cause	0 of 25	0 of 25	50	NCT02097485	Trial comparisons
Abametapir Lotion 0.74% w/w vs Vehicle Lotion: serious adverse events	0 of 25	0 of 25	50	NCT02097485	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
26092045	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003472

GET https://conductscience.org/api/diseases/v1/MONDO_0003472/drugs

API reference For AI assistants